Carmine Stengone, Contineum Therapeutics CEO and president

Con­tineum Ther­a­peu­tics files for IPO with MS drug in PhII

Clin­i­cal-stage biotech Con­tineum Ther­a­peu­tics, which un­til re­cent­ly went by the name Pipeline Ther­a­peu­tics, on Fri­day re­vealed plans to go pub­lic un­der the Nas­daq tick­er …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA